Pulse Biosciences Inc
PLSE
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.78B
Close$
$1.08
98% downside
Current Fair Value
98% downsideOvervalued by 98% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.78 Billion |
|---|---|
| Enterprise Value | $3.69 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.08 |
| Beta | 1.57 |
| Outstanding Shares | 69,200,020 |
Return
| Return on Equity | -80.46% |
|---|---|
| Return on Assets | -69.27% |
| Return on Invested Capital | -78.27% |
Valuation & Multiples
| P/E Ratio | -45.32 |
|---|---|
| PEG | -158.25 |
| Price to Sales | - |
| Price to Book Ratio | 53.02 |
| Enterprise Value to Revenue | 4922.13 |
| Enterprise Value to EBIT | -45.04 |
| Enterprise Value to Net Income | -47 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.07 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 11, 2026
EPS Estimate
$-0.31
Average shareholder expectationRevenue Estimate
$533,333
Average shareholder expectationNext Earnings Call
Expected Date
November 4, 2026
EPS Estimate
$-0.31
Average shareholder expectationRevenue Estimate
$520,833
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 30.47% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.02%▼ 15.68% |
|---|---|
| Total Invested | $721,944▼ 99.76% |
| Investors Holding | 8▼ 104.00% |
ESG Score
No data
About Pulse Biosciences Inc
95 employeesPulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients. The CellFX® System is the first commercial product to harness the distinctive ad...